



December 15, 2022

To:
Medicines Patent Pool
Rue de Varembe 7, Geneva 1202, Switzerland
By registered letter and email

RE: Termination of the License Agreement

Dear Sirs,


We hereby refer to the License Agreement dated March 7, 2022 (the "**Agreement**") by and between Teva Pharmaceutical Industries Ltd. ("**Teva**") and Medicines Patent Pool ("**MPP**") whereby MPP granted to Teva, inter alia, a Non-Exclusive license to the rights listed in Section 2 of the Agreement, all as defined in the Agreement.

Pursuant to Section 12.7 of the Agreement, Teva hereby notifies MPP of the termination of the Agreement. The termination shall enter into force effective as of January 14, 2023 (the "**Effective Date**"). Consequently, all the Parties' rights and obligations under the Agreement shall cease as of the Effective Date, except those obligations that are meant to survive following termination according to the Agreement and applicable law, as the case may be.

We thank you for the opportunity.

Sincerely,

Teva Pharmaceutical Industries Ltd.

Signature: 

Name: Eli Shani

Designation: EVP, Global Marketing & Portfolio

Signature: 

Name: Alex Nesbitt

Designation: VP Alliance Management



Digitally signed by
Yannai Strauss
Date: 2022.12.14
09:37:33 +02'00'

Teva Pharmaceutical Industries Ltd.

124 Dvora Hanevia St., Tel Aviv, Israel. Tel: +972.3.9267267 Fax: +972.3. 9234050 www.tevapharm.com